Compounds > ym 9429
Page last updated: 2024-12-07

ym 9429

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

YM 9429: a potent and specific teratogen; induces cleft palate in CD rats; inhibits dehydrocholesterol reductase [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID115195
SCHEMBL ID11443208
SCHEMBL ID11443207
MeSH IDM0224744

Synonyms (15)

Synonym
cis-1-(4-(p-monthane-8-yloxy)phenyl)piperidine
piperidine, 1-(4-(1-methyl-1-(4-methylcyclohexyl)ethoxy)phenyl)-, cis-
1-(4-(1-methyl-1-(cis-4-methylcyclohexyl)ethoxy)phenyl)piperidine
ym-9429
cis-1-(4-(1-methyl-1-(4-methylcyclohexyl)ethoxy)phenyl)piperidine
ym9429
cis-1-(4-(p-menthane-8-yloxy)phenyl)piperidine
ym 9429
72056-79-2
1-[4-[2-(4-methylcyclohexyl)propan-2-yloxy]phenyl]piperidine
SCHEMBL11443208
SCHEMBL11443207
1-(4-{[2-(4-methylcyclohexyl)propan-2-yl]oxy}phenyl)piperidine
DTXSID10992785
AKOS040754530
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (80.00)18.2507
2000's1 (20.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.66 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
lathosterol
lathosterol: RN given refers to (3beta,5alpha)-isomer. 5alpha-cholest-7-en-3beta-ol : A cholestanoid that is (5alpha)-cholest-7-ene substituted by a beta-hydroxy group at position 3.		1.99103beta-sterol;
C27-steroid;
cholestanoid;
Delta(7)-sterol		human metabolite;
mouse metabolite
mevalonic acid
Mevalonic Acid: A dihydroxy monocarboxylic acid and precursor in the biosynthetic pathway known as the mevalonate pathway, which produces terpenes and steroids that are vital for diverse cellular functions.. mevalonic acid : A racemate composed of equimolar amounts of (R)- and (S)-mevalonic acid.. (R)-mevalonic acid : The (R)-enantiomer of mevalonic acid.		1.99103,5-dihydroxy-3-methylpentanoic acid
mevalonolactone
mevalonolactone: RN given refers to unlabeled cpd without isomeric designation; structure. mevalonolactone : A racemate comprising equimolar amounts of (R)-mevalonolactone and (S)-mevalonolactone.		1.99104-hydroxy-4-methyloxan-2-onefungal metabolite;
plant metabolite
bm 15766
BM 15766: 7-dehydrocholesterol reductase antagonist		1.9910
piperidines
Piperidines: A family of hexahydropyridines.		3.0950
ConditionIndicatedRelationship StrengthStudiesTrials
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		02.3920
Abnormalities, Multiple
Congenital abnormalities that affect more than one organ or body structure.		01.9810
Cleft Palate, Isolated
[description not available]		02.3920
Abnormalities, Drug-Induced
Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment.		01.9810
Cleft Palate
Congenital fissure of the soft and/or hard palate, due to faulty fusion.		02.3920
7-Dehydrocholesterol Reductase Deficiency
[description not available]		01.9910
Experimental Hepatoma
[description not available]		01.9910
Smith-Lemli-Opitz Syndrome
An autosomal recessive disorder of CHOLESTEROL metabolism. It is caused by a deficiency of 7-dehydrocholesterol reductase, the enzyme that converts 7-dehydrocholesterol to cholesterol, leading to an abnormally low plasma cholesterol. This syndrome is characterized by multiple CONGENITAL ABNORMALITIES, growth deficiency, and INTELLECTUAL DISABILITY.		01.9910